Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San ...

Add Yahoo as a preferred source to see more of our stories on Google. “The term glaucoma refers to a group of diseases that cause permanent damage to the optic nerve, which is the cable that connects ...

Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmologyFirst ...

Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years. Neil Minkoff, MD: Where do we see glaucoma therapy going in the next 24 to 36 months, due to ...

Explore the latest research on glaucoma treatment and the role of immune cells in eye pressure regulation for better outcomes ...

Looking back, glaucoma specialists like Dr. Christine Funke of Barnet Dulaney Perkins Eye Center can remember a time not long ago when treatment options for the eye condition were greatly limited.

Artelo Biosciences (ARTL) stock jumped 40% after announcing a fully-funded glaucoma trial for ART27.13 with Belfast Health and Social Care Trust.

Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial ...

Dr Laila Raman-Abdulla, an ophthalmologist, is urging residents to prioritise regular eye examinations this March as part of World Glaucoma Month. The global awareness campaign aims to educate the ...

Please provide your email address to receive an email when new articles are posted on . “Glaucoma medication is associated with changes in meibomian glands morphology, including decreased acinar area, ...